

a1
Contd

administration by an anesthesiologist and the benefits of treatment using inhaled NO of hypoxemia relieving effect and/or smooth muscle constriction relieving effect, and additionally would provide antimicrobial effect and anti-inflammatory activity, and these activities would be provided with less toxicities than previous alternative therapies. The totality of the benefits is important, for example, not only in respect to treatment of asthma, for example, which is associated with smooth muscle constriction in lung and can be associated with hypoxemia, and where lung infection can be a secondary problem, but also in respect to cystic fibrosis where airway lining can be impaired to the extent that relaxing of the airway is not therapeutic, but where antimicrobial effect is important to treat infection associated with cystic fibrosis or where increased GSNO or glutathione (GSH) reactive compounds can upregulate the cystic fibrosis transmembrane regulator. In respect to treating cystic fibrosis, inhaled gaseous GSNO repleting or increase causing agents also function better than inhaled NO because they cause increase in cystic fibrosis transmembrane regulator and inhaled NO does not and/or are less toxic than NO.

Please replace the paragraph beginning at page 8, line 20, with paragraph:

a2

There is overlap for the treating agents for administration as a gas for the method herein with the treating agents of 09/390,215 which are compounds capable of being administered as a gas, having an NO group and having a hypoxemia relieving and smooth muscle constriction relieving effect with said NO group being bound in said compound so it does not form NO₂ or NO_x in the presence of oxygen or reactive oxygen species at body temperature where NO_x is NO, N₂O₃, N₂O₄, OONO⁻, OONO• and any products of their interaction with NO or NO₂.
